美罗培南，或译美洛培南，是一种有非常广泛抗菌性及可供注射的抗生素，用于治疗多种不同的感染，包括脑膜炎及肺炎。它是一种β内酰胺类抗生素，属于碳青霉烯的分类下。

美罗培南是由日本的住友制药所发展，并由阿斯利康以「Merrem®」及「Meronem®」的商标在日本以外的地方发行。

与亚安培南不同，美罗培南对肾脏内的脱氢酶较稳定，能在不使用西司他丁的情况下用药。它会渗透入脑脊液。美罗培南，相比起亚安培南亦能减低引致癫痫的风险。

Meropenem is an ultra-broad-spectrum injectable antibiotic used to treat a wide variety of infections. It is a β-lactam and belongs to the subgroup of carbapenem, similar to imipenem and ertapenem. Meropenem was originally developed by Dainippon Sumitomo Pharma. It gained US FDA approval in July 1996. It penetrates well into many tissues and body fluids, including cerebrospinal fluid, bile, heart valve, lung, and peritoneal fluid. It was initially marketed by AstraZeneca under the trade name Merrem.